

Press release
August 1, 2008
Kungsbacka, Sweden

Utilization of authorization within Vitrolife to repurchase own shares

The Annual General Meeting on April 29, 2008, of Vitrolife AB (publ) approved the proposal to authorize the Board of Directors to acquire the company's own shares for the purpose of adjusting the company's capital structure and/or use repurchased shares in connection with the acquisition of a company or business. The company's Board has now decided to utilize this authorization.

The shares will be purchased over the OMX Nordic Exchange Stockholm at a price within the quoted price range at any given time when the Board finds it favourable for the company's shareholders.

Purchase can be made as of August 2, 2008, until the next Annual General Meeting in 2009. No acquisitions will be made during a 30-day period prior to the announcement of quarterly results, the day of announcement included.

The total number of outstanding shares in Vitrolife is 19,800,157 and the maximum number of shares which can be repurchased is 1,980,015.

August 1, 2008
Kungsbacka, Sweden

Vitrolife AB (publ)

Queries should be addressed to:

Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media) and advanced one-time instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 140 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share is listed on the OMX Nordic Exchange Stockholm's Nordic Small Cap list.

Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

The information in this press release is such as that which Vitrolife is required to publish in accordance with the Securities Exchange and Clearing Operations Act. The information was submitted for publication on August 1, 2008 at 10.30 am.